Iniparib

依尼帕尼

Report date: 2025/04/24 15:28:59
NME

Base Information

Drug NameIniparib
Drug Alias NameIniparibum艾尼帕利NIBAINO2BABSI-201 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPoly (ADP-Ribose) polymerase 1 inhibitors
TargetsPoly (ADP-Ribose) polymerase 1
Therapy Area/IndicationsBrain metastasesMetastatic breast cancerSolid tumours +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[16] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBiPar Sciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiPar Sciences IncInstitut Regional Du Cancer De MontpellierSanofi
Active IndicationsN/A
Inactive IndicationsBrain metastasesMetastatic breast cancerSolid tumours +[12] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG